Industrial demand flexibility: A German case study

Autor: Sabine Löbbe, André Hackbarth, Heinz Hagenlocher, Uwe Ziegler

Business opportunities for energy providers to utilize flexible industrial demand are platform-based, connecting small and medium-sized enterprises (SMEs) to a virtual power plant (VPP) in complex ecosystems. Unlike in other VPPs, the focus is on par

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f5ef6d6c8050e6422c25fb9108dc16ce
https://doi.org/10.1016/b978-0-12-823810-3.00009-1

Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)

Autor: Marie M. Michelsen, Anna Sandberg, Mark Warren, Esteban Jódar, Stephen C. Bain, William H. Polonsky, Rosangela Rea, Signe Harring, Uwe Ziegler, Tina Vilsbøll

Publikováno v: Diabetes, Obesity & Metabolism
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
Jódar, E, Michelsen, M, Polonsky, W, Réa, R, Sandberg, A, Vilsbøll, T, Warren, M, Harring, S, Ziegler, U & Bain, S 2020, ' Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6) ', Diabetes, Obesity and Metabolism, vol. 22, no. 8, pp. 1339-1347 . https://doi.org/10.1111/dom.14039

Aim: To assess what drives change in health-related quality of life (HRQoL) in type 2 diabetes in the SUSTAIN 6 trial and identify potential mediators of the treatment effect of semaglutide on HRQoL scores. Materials and methods: The Short Form (SF)-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94fbb9a80ad62238173f28d53249d54a
https://hdl.handle.net/11268/10012

1003-P: Clinical Response (HbA1c ≥1% and/or Body Weight ≥5% Reduction) to Semaglutide by Baseline HbA1c and Body Weight in the SUSTAIN Program

Autor: Julie F. Larsen, Signe Harring Østoft, Vanita R. Aroda, Rosangela Rea, Danny Sugimoto, Uwe Ziegler, Tina Vilsbøll

Publikováno v: Diabetes. 68

The SUSTAIN clinical development program assessed semaglutide once weekly, a glucagon-like peptide-1 (GLP-1) analog, across the continuum of type 2 diabetes (T2D) care, including in drug-naïve subjects and those on a background of oral antidiabetic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ae9a349aea586cd56c063e75b1797fac
https://doi.org/10.2337/db19-1003-p

86 - Clinical Response (HbA1C ≥1% and/or Body Weight ≥5% Reduction) to Semaglutide by Baseline HbA1C and Body Weight in the SUSTAIN Program

Autor: Vanita R. Aroda, Uwe Ziegler, Danny Sugimoto, Tina Vilsbøll, Rosangela Rea, Signe Harring Østoft, Akshay Jain, Julie F. Larsen

Publikováno v: Canadian Journal of Diabetes. 43:S31-S32

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::59c9dd18fa7057ab984a39f8ffe0601f
https://doi.org/10.1016/j.jcjd.2019.07.095

Brain and lung metastasis of alveolar echinococcosis in a refugee from a hyperendemic area

Autor: August Stich, Wolfgang Müllges, Uwe Ziegler, David R. Weise, Dennis Tappe, Andreas Müller

Publikováno v: Journal of Medical Microbiology. 57:1420-1423

Alveolar echinococcosis (AE) of the liver with cerebral and pulmonary metastasis was diagnosed in a Tibetan monk who initially presented with severe headache to an emergency department in Germany. Multiple lesions with perifocal oedema and severe com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa8442c358ac93042d2f7ff29dc88be4
https://doi.org/10.1099/jmm.0.2008/002816-0